Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
[google_news title=”” keyword=”Heroin vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Heroin vaccine
- IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Studyon May 13, 2024 at 7:05 am
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollmentTopline results expected ...
- Alzheimer’s vaccine licensing deal boosts AC Immuneon May 13, 2024 at 5:47 am
AC Immune shares jumped more than 50% premarket on Monday after the company announced a licensing deal with Takeda Pharmaceutical Co. for its experimental Alzheimer’s disease vaccine.
- Study: COVID-19 vaccine tied to longer survival in heart failure patientson May 11, 2024 at 5:00 pm
Current clinical focus on understanding and unlocking every drug’s full potential has researchers looking at what the COVID-19 vaccine can do — beyond staving off or lessening severity of the virus. A ...
- Cancer Vaccine Triggers Fierce Immune Response to Fight Malignant Brain Tumors in Human Patientson May 11, 2024 at 6:37 am
In the first human trial, an mRNA cancer vaccine at the University of Florida triggered immune systems to fiercely attack glioblastoma.
- FDA Approves IND of Epstein-Barr mRNA Cancer Vaccine WGc-043on May 10, 2024 at 1:17 pm
The FDA has approved the investigational new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine. Epstein-Barr virus is correlated with several malignancies, making this ...
- French, US drug firms team up for Covid-flu shoton May 10, 2024 at 11:13 am
French pharmaceutical giant Sanofi and struggling US rival Novavax announced Friday an alliance to sell a Covid vaccine and develop another that combines ...
- Moderna says FDA delaying decision on RSV vaccine approvalon May 10, 2024 at 10:39 am
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative constraints” at the Food and Drug Administration, as the company works to get its ...
- FDA delays decision on Moderna RSV vaccineon May 10, 2024 at 9:31 am
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.
- US FDA pushes decision on Moderna's RSV vaccine to end of this monthon May 10, 2024 at 5:35 am
The U.S. drug regulator has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine due to "administrative constraints" and will complete the review by the end of this month, ...
- A new cholera vaccine will increase supply, but will it be enough to manage global outbreaks?on May 9, 2024 at 1:31 am
Along with a new manufacturing plant that will be at full capacity next year, EuBiologics will be able to produce 50 million cholera vaccine doses in 2024, and 80 million in 2025, said Lynch — most of ...
via Bing News